Фибромускулярная дисплазия почечных артерий. Состояние проблемы

В настоящей статье рассмотрены основные вопросы, касающиеся выбора тактики лечения больных с фибромускулярной дисплазией почечных артерий. Продемонстрированы ключевые положения российских, европейских и американских согласительных документов. Уделено внимание последним исследованиям, отражающим современные представления об этиологии, факторах риска, генетических предикторах развития заболевания, а также хирургических подходах в лечении.

1. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24(2):164–189. https://doi.org/10.1177/1358863X18821816

2. Гришкевич А. А., Ревишвили А. Ш., Зотиков А. Е., Покровский А. В., Адырхаев З. А., Алекян Б. Г. и др. Хирургия почечных сосудов. М.: Фонд «Русские витязи», 2021. 300 с.

3. Plouin PF, Baguet JP, Thony F, Ormezzano O, Azarine A, Silhol F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). Hypertension. 2017;70(3):652–58. https://doi.org/10.1161/HYPERTENSIONAHA.117.09539

4. Olin JW, Froehlich J, Gu X, Bacharach JM, Eagle K, Gray BH, et al. The United States Registry for fibromuscular dysplasia: results in the first 447 patients. Circulation. 2012;125(25): 3182–90. https://doi.org/10.1161/CIRCULATIONAHA.112.091223

5. Pappaccogli M, Di Monaco S, Warchoł-Celińska E, Lorthioir A, Amar L, Aparicio LS, et al. The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)-clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovasc Res. 2021;117(3):950–959. https://doi.org/10.1093/cvr/cvaa102

6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339

7. Lenz T. Behandlung der Nierenarterienstenose im Jahr 2021. [Treatment of renal artery stenosis in the year 2021]. Internist (Berl). 2021;62(3):252–62. https://doi.org/10.1007/s00108-020-00935-5

8. Идрисов И. А., Хафизов Т. Н., Хафизов Р. Р., Шаймуратов И. Х., Абхаликова Е. Е., Идрисова Л. Р. Стеноз почечных артерий. Диагностика и тактика лечения пациентов (обзор литературы). Креативная хирургия и онкология. 2021;11(3):235–243. https://doi.org/10.24060/2076-3093-2021-11-3-235-243.

9. Rana MN, Al-Kindi SG. Prevalence and manifestations of diagnosed fibromuscular dysplasia by sex and race: analysis of > 4500 FMD cases in the United States. Heart Lung. 2021;50(1):168–173. https://doi.org/10.1016/j.hrtlng.2020.09.022

10. Persu A, Van der Niepen P, Touzé E, Gevaert S, Berra E, Mace P, et al. Revisiting fibromuscular dysplasia: rationale of the european fibromuscular dysplasia initiative. Hypertension. 2016;68(4):832–9.

11. Чазова И. Е., Чихладзе Н. М., Блинова Н. В., Белая Ж. Е., Данилов Н. М., Елфимова Е. М. и др. Евразийские клинические рекомендации по диагностике и лечению вторичных (симптоматических) форм артериальной гипертонии (2022). Евразийский Кардиологический Журнал. 2023;(1):6–65. https://doi.org/10.38109/2225-1685-2023-1-6-65

12. Щелкова Г. В., Данилов Н. М., Эркенова А. М., Яровой С. Ю., Матчин Ю. Г., Миронова О. Ю. и др. Консенсус по диагностике и лечению реноваскулярной артериальной гипертонии. Системные гипертензии. 2023;20(2):5–20. https://doi.org/10.38109/2075-082X-2023-2-5-20

13. Baradhi KM, Bream P. Fibromuscular dysplasia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021

14. Shivapour DM, Erwin P, Kim ESh. Epidemiology of fibromuscular dysplasia: A review of the literature. Vasc Med. 2016;21(4):376–81. https://doi.org/10.1177/1358863X16637913

15. Wu HHL, Damle A, Chinnadurai R, Chrysochou C. Lessons for the clinical nephrologist: fibromuscular dysplasia in older adults. J Nephrol. 2025;38(1):283–288. https://doi.org/10.1007/s40620-024-02039-x

16. Leadbetter WF, Burkland CE. Hypertension in unilateral renal disease. J Urol. 1938;39:611–26. https://doi.org/10.1016/S0022-5347(17)71895-2

17. McCormack LJ, Hazard JB, Poutasse EF. Obstructive lesions of the renal artery associated with remediable hypertension. Am J Pathol.1958;34:582.

18. Harrison EG, Jr McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc. 1971;46:161–7.

19. Chrysant SG, Chrysant GS. Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries. Cardiovasc Diagn Ther. 2014;4(1):36–43. https://doi.org/10.3978/j.issn.2223-3652.2014.02.01

20. Akiba Y, Endo A, Suzuki K, Hoshino Y, Suzuki T, Fujii Y. Fibromuscular dysplasia of coronary and brachial artery. Can J Cardiol. 2018;34(12):1689.e3–1689.e4. https://doi.org/10.1016/j.cjca.2018.09.002

21. Babapoor-Farrokhran S, Port Z. Fibromuscular dysplasia involving the coronary arteries. Methodist Debakey Cardiovasc J. 2021;17(1):71–72. https://doi.org/10.14797/OYIY5154

22. Ko M, Kamimura K, Sakamaki A, Niwa Y, Tominaga K, Mizuno K, et al. Rare mesenteric arterial diseases: fibromuscular dysplasia and segmental arterial mediolysis and literature review. Intern Med. 2019;58(23):3393–3400. https://doi.org/10.2169/internalmedicine.3094-19

23. Okazaki J, Guntani A, Homma K, Kyuragi R, Kawakubo E, Maehara Y. Fibromuscular dysplasia of the lower extremities. Ann Vasc Dis. 2011;4(2):143–9. https://doi.org/10.3400/avd.cr.10.01027

24. Antonescu I, Knowles M, Wirtz E, Pascarella L.An unusual case of bilateral upper extremity ischemia caused by forearm vessel fibromuscular dysplasia. Ann Vasc Surg. 2019;56:353.e7–353.e11. https://doi.org/doi.org/10.1016/j.avsg.2018.08.110

25. Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X. Fibromuscular dysplasia. Orphanet J Rare Dis. 2007;2:28. https://doi.org/10.1186/1750-1172-2-28

26. Gladstien K, Rushton AR, Kidd KK. Penetrance estimates and recurrence risks for fibromuscular dysplasia. Clin Genet. 1980;17(2):115–6. https://doi.org/10.1111/j.1399-0004.1980.tb00117.x

27. Ganesh SK, Morissette R, Xu Z, Schoenhoff F, Griswold BF, Yang J, et al. Clinical and biochemical profiles suggest fibromuscular dysplasia is a systemic disease with altered TGF-β expression and connective tissue features. FASEB J. 2014;28:3313– 3324. https://doi.org/10.1096/fj.14-251207

28. Kiando SR, Tucker NR, Castro-Vega LJ, Katz A, D’Escamard V, Tréard C, et al. PHACTR1 is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance. PLoS Genet. 2016;12(10): e1006367. https://doi.org/10.1371/journal.pgen.1006367

29. Shimabukuro M. A new plausible link between lysophosphatidylcholine, TGF-β, and fibromuscular dysplasia. J Atheroscler Thromb. 2016;23(6):665–7. https://doi.org/10.5551/jat.ED040

30. Petropoulos T, Shah A, Dueck A, Hawkes C, Tobe SW, Kingston W, et al. Fibromuscular dysplasia: a focused review for the cardiologist. CJC Open. 2024;6(11):1274–1288. https://doi.org/10.1016/j.cjco.2024.07.014

31. Sharma AM, Kline B. The United States registry for fibromuscular dysplasia: new findings and breaking myths. Tech Vasc Interv Radiol. 2014;17(4):258–63. https://doi.org/10.1053/j.tvir.2014.11.007

32. Kadian-Dodov D, Gornik HL, Gu X, Froehlich J, Bacharach JM, Chi YW, et al. Dissection and aneurysm in patients with fibromuscular dysplasia: findings from the U. S. Registry for FMD. J Am Coll Cardiol. 2016;68(2):176–85. https://doi.org/10.1016/j.jacc.2016.04.044

33. Bloch MJ, Basile J. Clinical insights into the diagnosis and management of renovascular disease. An evidence-based review. Minerva Med. 2004;95(5):357–73

34. O’Connor S, Gornik HL, Froehlich JB, Gu X, Gray BH, Mace PD, et al. Smoking and adverse outcomes in fibromuscular dysplasia: U. S. Registry report. J Am Coll Cardiol. 2016;67(14): 1750–1. https://doi.org/10.1016/j.jacc.2016.01.058

35. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71: e13-e115. https://doi.org/10.1161/HYP.0000000000000065

36. Zeller T. Renal artery stenosis: epidemiology, clinical manifestation, and percutaneous endovascular therapy. J Interv Cardiol. 2005;18(6):497–506. https://doi.org/10.1111/j.1540–8183.2005.00092.x

37. Warchol-Celinska E, Prejbisz A, Dobrowolski P, Klisiewicz A, Kadziela J, Florczak E, et al. Systematic and multidisciplinary evaluation of fibromuscular dysplasia patients reveals high prevalence of previously undetected fibromuscular dysplasia lesions and affects clinical decisions: the ARCADIA-POL study. Hypertension. 2020;75(4):1102–1109. https://doi.org/10.1161/HYPERTENSIONAHA.119.13239

38. Wang LC, Scott DJ, Clemens MS, Hislop SJ, Arthurs ZM. Mechanism of stent failure in a patient with fibromuscular dysplasia following renal artery stenting. Ann Vasc Surg. 2015;29(1):123. e19–21. https://doi.org/10.1016/j.avsg.2014.08.002

39. Kądziela J, Jóźwik-Plebanek K, Pappaccogli M, van der Niepen P, Prejbisz A, Dobrowolski P, et al. Risks and benefits of renal artery stenting in fibromuscular dysplasia: lessons from the ARCADIA-POL study. Vasc Med. 2024;29(1):50–57. https://doi.org/10.1177/1358863X231210523

40. Cadour F, Silhol F, Iline N, Giorgi R, Lorthioir A, Amar L, et al. Insights from intravascular pressure measurement of renal artery revascularization in patients with fibromuscular dysplasia: The DYSART study. J Vasc Surg. 2022;75(3):939–49. e1. https://doi.org/10.1016/j.jvs.2021.09.023

41. Meuse MA, Turba UC, Sabri SS, Park AW, Saad WE, Angle JF, et al. Treatment of renal artery fibromuscular dysplasia. Tech Vasc Interv Radiol. 2010;13(2):126–33. https://doi.org/10.1053/j.tvir.2010.02.007

42. Sciacca L, Ciocca RG, Eslami MH, Messina LM. Endovascular treatment of renal artery aneurysm secondary to fibromuscular dysplasia: a case report. Ann Vasc Surg. 2009;23(4):536. e9–12. https://doi.org/10.1016/j.avsg.2008.11.011

43. Яковлева Е. В., Волошинова Е. В., Тяпкина М. А., Махина В. И. Терапия. Эффективность баллонной ангиопластики в лечении фибромускулярной дисплазии почечных артерий (10-летнее наблюдение). Терапия. 2023;9(3):136–40. https://dx.doi.org/10.18565/therapy.2023.3.136–140

44. Itani HS, Mudawwar WA, Tanios BY, Alam SE, Haddad FF. First use of a drug-eluting balloon in the treatment of acute renal artery occlusion and in-stent restenosis. Am J Med Sci. 2013;346(3):244–6. https://doi.org/10.1097/MAJ.0b013e31828b2b7f

45. Hecht T, Esmaeili A, Behnke-Hall K. Balloon angioplasty of the bilateral renal arteries by Takayasu arteritis with a paclitaxeleluting balloon. Cardiol Young. 2015;25(7):1431–4. https://doi.org/10.1017/S1047951114001930

46. Li X, Zhang J, Meng Y, Yang L, Wang F, Li B, et al. Transplant renal artery stenosis caused by the stretch of an artery branch: a case report and literature review. BMC Nephrol. 2018;19(1):56. https://doi.org/10.1186/s12882-018-0856-y

47. Шукуров Ф. Б., Талиуридзе М. Т., Харлап М. С., Кардашова М. А., Федотова Н. П., Васильев Д. К. и др. Лечение фибромускулярной дисплазии почечной артерии посредством ангиопластики баллоном с лекарственным покрытием и внутрисосудистой визуализации: клинический случай. Российский кардиологический журнал. 2024;29(2S):5774. https://doi.org/10.15829/1560-4071-2024-5774

48. Song X, Fu Y, Lai Z, Di X, Zeng R, Shao J, et al. Drug-coated balloon for treatment of non-atherosclerotic renal artery stenosis-a multi-center study. BMC Cardiovasc Disord. 2023;23(1):510. https://doi.org/10.1186/s12872-023-03484-5

49. Gavalas MV, Gasparis AP, Tassiopoulos AK, Loh S, Labropoulos N. Long-term follow-up for percutaneous transluminal angioplasty in renal artery fibromuscular dysplasia. Int Angiol. 2015;34(6):529–37.

50. Fujihara M, Fukata M, Higashimori A, Nakamura H, Odashiro K, Yokoi Y. Short- and mid-term results of balloon angioplasty for renal artery fibromuscular dysplasia. Cardiovasc Interv Ther. 2014;29(4):293–9. https://doi.org10.1007/s12928-014-0253-9

51. Brekke IB, Sødal G, Jakobsen A, Bentdal O, Pfeffer P, Albrechtsen D, et al. Fibro-muscular renal artery disease treated by extracorporeal vascular reconstruction and renal autotransplantation: short- and long-term results. Eur J Vasc Surg. 1992;6(5):471–6. https://doi.org/10.1016/s0950-821x(05)80619-x

52. Goodman J, Kulkarni S, Selvarajah V, Hilliard N, Russell N, Wilkinson IB. Renal autotransplantation for uncontrolled hypertension in nonatherosclerotic renal artery stenosis-2 case reports and a brief review of the literature. Hypertension. 2024;81(4):669– 675. https://doi.org/10.1161/HYPERTENSIONAHA.123.19878